These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23363473)

  • 1. Brain dopamine-serotonin vesicular transport disease and its treatment.
    Rilstone JJ; Alkhater RA; Minassian BA
    N Engl J Med; 2013 Feb; 368(6):543-50. PubMed ID: 23363473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic disorders causing movement disorders in childhood; an addition to the list.
    Fox SH
    Mov Disord; 2013 May; 28(5):584. PubMed ID: 23677896
    [No Abstract]   [Full Text] [Related]  

  • 3. A case report of infantile parkinsonism-dystonia-2 caused by homozygous mutation in the
    Zhai H; Zheng Y; He Y; Zhang Y; Guo Z; Cui W; Sun L
    Int J Neurosci; 2023 May; 133(5):574-577. PubMed ID: 34078222
    [No Abstract]   [Full Text] [Related]  

  • 4. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease.
    Rath M; Korenke GC; Najm J; Hoffmann GF; Hagendorff A; Strom TM; Felbor U
    J Neurol Sci; 2017 Aug; 379():296-297. PubMed ID: 28716265
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals.
    Saida K; Maroofian R; Sengoku T; Mitani T; Pagnamenta AT; Marafi D; Zaki MS; O'Brien TJ; Karimiani EG; Kaiyrzhanov R; Takizawa M; Ohori S; Leong HY; Akay G; Galehdari H; Zamani M; Romy R; Carroll CJ; Toosi MB; Ashrafzadeh F; Imannezhad S; Malek H; Ahangari N; Tomoum H; Gowda VK; Srinivasan VM; Murphy D; Dominik N; Elbendary HM; Rafat K; Yilmaz S; Kanmaz S; Serin M; Krishnakumar D; Gardham A; Maw A; Rao TS; Alsubhi S; Srour M; Buhas D; Jewett T; Goldberg RE; Shamseldin H; Frengen E; Misceo D; Strømme P; Magliocco Ceroni JR; Kim CA; Yesil G; Sengenc E; Guler S; Hull M; Parnes M; Aktas D; Anlar B; Bayram Y; Pehlivan D; Posey JE; Alavi S; Madani Manshadi SA; Alzaidan H; Al-Owain M; Alabdi L; Abdulwahab F; Sekiguchi F; Hamanaka K; Fujita A; Uchiyama Y; Mizuguchi T; Miyatake S; Miyake N; Elshafie RM; Salayev K; Guliyeva U; Alkuraya FS; Gleeson JG; Monaghan KG; Langley KG; Yang H; Motavaf M; Safari S; Alipour M; Ogata K; Brown AEX; Lupski JR; Houlden H; Matsumoto N
    Genet Med; 2023 Jan; 25(1):90-102. PubMed ID: 36318270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.
    Isingrini E; Perret L; Rainer Q; Sagueby S; Moquin L; Gratton A; Giros B
    J Psychiatry Neurosci; 2016 Apr; 41(3):169-81. PubMed ID: 26505143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder.
    Jacobsen JC; Wilson C; Cunningham V; Glamuzina E; Prosser DO; Love DR; Burgess T; Taylor J; Swan B; Hill R; Robertson SP; Snell RG; Lehnert K
    J Inherit Metab Dis; 2016 Mar; 39(2):305-8. PubMed ID: 26497564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [
    Hankosky ER; Joolakanti SR; Nickell JR; Janganati V; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5467-5472. PubMed ID: 29153425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia.
    Kurian MA; Zhen J; Cheng SY; Li Y; Mordekar SR; Jardine P; Morgan NV; Meyer E; Tee L; Pasha S; Wassmer E; Heales SJ; Gissen P; Reith ME; Maher ER
    J Clin Invest; 2009 Jun; 119(6):1595-603. PubMed ID: 19478460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
    Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ
    Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism.
    Mooslehner KA; Chan PM; Xu W; Liu L; Smadja C; Humby T; Allen ND; Wilkinson LS; Emson PC
    Mol Cell Biol; 2001 Aug; 21(16):5321-31. PubMed ID: 11463816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infantile parkinsonism-dystonia due to dopamine transporter gene mutations: another genetic twist.
    Blackstone C
    Lancet Neurol; 2011 Jan; 10(1):24-5. PubMed ID: 21112252
    [No Abstract]   [Full Text] [Related]  

  • 17. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters.
    Mulvihill KG
    Neurochem Int; 2019 Jan; 122():94-105. PubMed ID: 30465801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine transporter as a target molecule for psychostimulants.
    Sora I; Li B; Fumushima S; Fukui A; Arime Y; Kasahara Y; Tomita H; Ikeda K
    Int Rev Neurobiol; 2009; 85():29-33. PubMed ID: 19607959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.